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BACKGROUND Out-of-hospital cardiac arrest (OHCA) is a major public
health burden; annual incidence in the UK alone is estimated at 50,000;(1)
healthcare costs and resource expenditure - based on emergency response,
hospitalization and long-term care of survivors- arehuge; one cost estimate
placed the ﬁgure at $33 billion pa in the US.(2, 3) Prediction and prevention
remain a challenge:more thanhalf of OHCApresenting as the index cardiac
event.(4,5) In resuscitatedOHCAwith electrocardiographic (ECG) evidence
of ST-segment elevation myocardial infarction (STEMI) a growing body of
observational data supports immediate coronary angiography with good
outcomes; likely driven by access to facilities to diagnose and treat the
precipitating pathology of arrest (coronary angiographyþ/-PCI) and so-
phisticated post-cardiac arrest care; however, the management of patients
without ST elevation on the post resuscitation ECG or those with refractory
arrhythmias is less well deﬁned. The question as to whether all OHCA pa-
tients may beneﬁt from immediate coronary angiography and specialist
care remains unanswered and there is urgent need for a randomized
controlled trial. We propose testing a prehospital pathway that delivers
emergency carewith destination therapy: delivery of the patient directly to
a HAC to receive immediate coronary angiography þ/-PCI.
METHODS Hypothesis: Expedited transfer of patients to a HAC using a
hyperinvasive strategy of immediate coronary angiography þ/-PCI
following out-of-hospital ventricular ﬁbrillation arrest will confer a sur-
vival beneﬁt compared to the current standard of care. Methods: Pro-
spective, pan-London, multi-center, randomized control trial. Patients
with OHCA are randomized to one of two of the study arms: control
(standard of care) or intervention (straight to HAC for immediate coronary
angiography). The Pilot Study of 10 patients was conducted between Nov
2014 and March 2015, at a single UK site, randomized 1:1 to either im-
mediate coronary angiography (n¼5) or standard of care (n¼5). Inclusion
Criteria: Witnessed OHCA; pulseless VT/VF; age>18; absence of non-car-
diac cause (trauma, drowning). Exclusion Criteria: ST-Elevation myocar-
dial infarction on 12-Lead ECG; Pulseless Electrical Activity (PEA)/
Asystole; DNAR; suspected pregnancy. Primary Outcome: All-cause mor-
tality 30 days. Secondary: All-cause mortality 6, 12 months; neurological
status at discharge (capped at 30 days); major adverse cardiovascular &
cerebrovascular events (MACCE).
RESULTS Pilot study patient demographics and outcomes; *full data
extraction pending on 2 patients; abbreviations: CPR cardiopulmo-
nary resuscitation, ROSC return of spontaneous circulation, MACCE
major adverse cardiovascular and cerebrovascular event, LVEF left
ventricular ejection fraction.
CONCLUSIONS This pilot was hugely informative, demonstrating
feasibility of pre-hospital randomization and in-hospital care path-
ways and ease of recruitment. Full trial recruitment (N¼360) has
commenced.
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BACKGROUND Although recent studies have demonstrated the
safety & efﬁcacy of everolimus eluting bioabsorbable vascular scaffold
(BVS) in the management of stable coronary artery disease (CAD), but
there is lack of data regarding use of BVS for primary percutaneous
coronary intervention (PCI) in management ST segment elevation
myocardial infarction (STEMI). Aims: To evaluate immediate & short
term safety and efﬁcacy of the everolimus-eluting BVS in patients
with STEMI.METHODS It is a prospective non-randomized single center obser-
vational study. From January 2013 to February 2015, patients with
STEMI who received BVS implantation during primary PCI were
included in this study. Patients with Cardiogenic shock, with coexis-
tent severe noncardiac illness, and small caliber (<2.3mm) or large
caliber (>3.7 mm) infarct related vessels were not included.
RESULTS Among 248 patients of primary PCI, 40 patients received
BVS stent within this study period. It was a male predominated cohort.
Mean age was 59.2 þ/- 9 years. Thirty seven percent were smokers,
while 31% were diabetics and 27% were hypertensives. Eighty percent
patients had single vessel CAD. Femoral access was used in 51% cases.
Mean door-to-balloon time was 93þ/- 30 minutes. Anterior wall STEMI
was more frequent than inferior wall STEMI involving right coronary
artery territory. Mean BVS length and BVS diameter per patient was
24.6 þ/- 4.7 mm and 3.2 þ/- 0.3 mm, respectively. About 66% patients
received thromboaspiration during PCI and thrombolysis in myocar-
dial infarction (TIMI) III ﬂow was achieved in 94% patients. Four pa-
tients had intravascular imaging. Procedural success was achieved in
94% patients. Only one case had non cardiac death within one month.
All had a regular clinical follow up till May 2015. Twenty eight percent
patients had follow up angiogram within mean period of 8 þ/- 2.7
months. In all scaffold was functioning well.
CONCLUSIONS The use of the Absorb BVS in this cohort reﬂecting
day-to-day real world clinical practice is feasible and associated with
good procedural safety and angiographic success rate. In addition,
mean 10þ/- 4.8 month follow-up showed acceptable clinical out-
comes. From efﬁcacy and safety viewpoints BVS may be a considered
option in primary PCI for STEMI.
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BACKGROUND To investigate the clinical safety and long-term out-
comes of earlier complete revascularization for multivessel disease
(MVD) after primary percutaneous coronary intervention(PCI).
METHODS A total of 704 patients treated with primary angioplasty by
drug eluting stents for ST-elevation myocardial infarction with MVD
were enrolled from January 2009 to December 2012 and were divided
into two groups. 425 patients underwent PCI of the infarct-related
artery only (Infarct vessel PCI group); 279 patients underwent same
time or stage PCI of non-target vessel and achieved complete revas-
cularization within seven days of primary PCI at index admission
(Multivessel PCI). The clinical safety and long-term outcomes of all
patients were evaluated.
RESULTS Baseline characteristics were similar between two groups.
At a median of 3.4 years of follow up, compared with multivessel PCI,
PCI restricted to the infarct-related artery only was associated with
higher rate of MACE ( Major adverse cardiac event: Death and MI 3.2%
vs. 7.3%, P<0.05)However, no difference was found for target vessel
revascularization recurrence and stroke in these two groups. Kaplan
Meier curve showed that MACE free survival was much higher in
multivessel PCI group (93% vs. 90% P<0.05). Results of Cox regres-
sion models revealed that multivessel PCI was the protective factor
for patients (RR¼0.393, 95%CI: 0.181-0.854), chronic renal failure
(RR ¼ 11.725 95%CI: 4.141–33.200) and Killip 3 (RR¼4.514, 95%CI:
1.558–13.081) were the negative predicative factor for MACE.Multivessel PCI
(n[279)Culprit vessel PCI
(n[425) P valueFollow upDeath 5 (2.0) 15 (4.0) >0.05AMI 4 (1.6) 16 (4.3) >0.05TVR 17 (6.7) 18 (4.8) >0.05Stroke 9 (3.5) 9 (2.4) >0.05MACE (Death and MI) 9 (3.5) 30 (8.0) <0.05
